Viruses 2010, 2(6), 1279-1305; doi:10.3390/v2061279

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

, email, email and * email
Received: 9 March 2010; in revised form: 18 May 2010 / Accepted: 25 May 2010 / Published: 31 May 2010
(This article belongs to the Special Issue Hepatitis Viruses)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
Keywords: antiviral therapy; HBV therapy; nucleoside analogs; viral hepatitis
PDF Full-text Download PDF Full-Text [709 KB, uploaded 31 May 2010 15:46 CEST]

Export to BibTeX |

MDPI and ACS Style

De Clercq, E.; Férir, G.; Kaptein, S.; Neyts, J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses 2010, 2, 1279-1305.

AMA Style

De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses. 2010; 2(6):1279-1305.

Chicago/Turabian Style

De Clercq, Erik; Férir, Geoffrey; Kaptein, Suzanne; Neyts, Johan. 2010. "Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections." Viruses 2, no. 6: 1279-1305.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert